Drugs / ASN003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02961283 | Oct 2016 → Feb 2019 | colorectal neoplasm, melanoma, non-small cell lung carcinoma | Asana BioSciences | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-04-10 | Asana BioSciences | Asana BioSciences Announces Presentations of ASN003 (BRAF/PI3K inhibitor) and ASN007 (ERK1/2 inhibitor) at the American Association for Cancer Research Annual Meeting asanabio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02961283 ↗ |